Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors at 5 institutions in 3 countries.
C CastenmillerDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0001-7608-7390
M StiglerDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.ORCID 0000-0002-8890-5271
M E KirpasCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Mass; Harvard Medical School and Massachusetts General Hospital, Boston, Mass; Food Allergy Center, Massachusetts General Hospital, Boston, Mass, USA.ORCID 0000-0001-6027-7421
S VersteegDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-9729-3000
J H AkkerdaasDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-0247-1685
G Pena-CastellanosDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.ORCID 0000-0002-6882-4714
B R BlokhuisDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-9366-6404
S C DreskinDivision of Allergy and Clinical Immunology, Department of Medicine, University of Colorado, Aurora, Colorado, USA.ORCID 0000-0003-3548-5530
E C de JongDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-0410-3018
F RedegeldDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-8830-7960
W G ShrefflerCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Mass; Harvard Medical School and Massachusetts General Hospital, Boston, Mass; Food Allergy Center, Massachusetts General Hospital, Boston, Mass, USA.ORCID 0000-0001-6465-137X
L AglasDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.ORCID 0000-0002-1236-5934
R van ReeDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-0767-0894
Amsterdam University Medical Centers · NLUniversity of Salzburg · ATHarvard University · USUtrecht University · NLUniversity of Colorado Anschutz Medical Campus · US
Funding
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nutsR01AI165866 · NIAID · UNIVERSITY OF COLORADO DENVER · PI STEPHEN C DRESKIN · 2021 to 2026
$4.2M
Mapping the Critical Epitopes of Ara h 2 and Ara h 6R01AI099029 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DRESKIN, STEPHEN C · 2012 to 2015
$1.5M
Austrian Science Fund FWF P 32189NIAID NIH HHS R01 AI099029NIAID NIH HHS R01 AI165866
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity. · full record | OpenQuestion